Anantharaman R*, Arulkumar A, Madhusankar N, Kulasekaran M, Cherian S and Cherian KM
Department of Cardiology, Frontier Lifeline Hospital, IndiaFulltext PDF
Cardiac Allograft Vasculopathy (CAV) is the 'Achilles heel' of long term outcome following heart transplant. Even though the overall outcomes for heart transplant has improved over the last 4 decades, with survival after heart transplant reported 90%, 80% and 60% at 1, 3 and 10 years respectively, the long term survival is determined mainly by presence or absence of CAV. In this report we discuss the first case of re-do heart transplant done in India for CAV, 8 years following the initial transplant done in 2009 and we discuss the underlying pathology, treatment options and possible preventions of CAV in the current era.
Heart transplantation; Cardiac allograft vasculopathy
Anantharaman R, Arulkumar A, Madhusankar N, Kulasekaran M, Cherian S, Cherian KM. India's 1st Case of Re-Do Heart Transplantation for Cardiac Allograft Vasculopathy: A Case Report and Review of Literature. Ann Transplant Res. 2018;1(3):1011.